What We’re Reading: Predicting Weight Loss Response; Talc Baby Powder and Ovarian Cancer; Safeguarding IVF Access

Genetic Markers Predict Strong Response to Weight Loss Drug

Researchers have identified genetic markers that predict a strong response to semaglutide (Wegovy; Novo Nordisk), and they presented their findings at Digestive Disease Week, according to Reuters. Patients with these genetic profiles, characterized by a "hungry gut," showed significant weight loss compared with those who did not have the profiles, indicating the potential to more effectively tailor obesity treatments. Given semaglutide’s high cost, these findings could help pinpoint which patients would benefit most, optimizing both treatment outcomes and financial investment.

New Data Support Claims Linking J&J Talc Baby Powder, Ovarian Cancer

A new study has associated the use of talc-based baby powder with an increased risk of ovarian cancer, especially with frequent or long-term use, according to NBC News. This finding, based on data from the National Institutes of Health's Sister Study, lends support to over 50,000 lawsuits alleging Johnson & Johnson's talc products cause cancer. As legal proceedings consolidate in New Jersey, the company continues to deny these claims, despite proposing a multibillion-dollar settlement to resolve the lawsuits.

Legislation Proposed to Safeguard IVF Access Nationwide

Republican Senators Ted Cruz (TX) and Katie Britt (AL) have announced a new bill to protect nationwide access to in vitro fertilization (IVF) following an Alabama Supreme Court ruling that embryos created through IVF are children, according to The Hill. The legislation seeks to eliminate legal uncertainties and requires states to allow IVF as a condition for receiving federal Medicaid funding. Cruz and Britt emphasized the “pro-family” nature of IVF and the bill’s aim to ensure that prospective parents are not hindered by legal obstacles.